AVEO Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
Summary
is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The company is focused on developing and commercializing its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in as a treatment for renal cell carcinoma and other cancers. This press release contains forward-looking statements, such as those, among others, relating to AVEO’s expectations with respect to intended use of proceeds of the offering and the anticipated timing of receipt of top-line data in -3. Factors that may cause such a difference include, without limitation, risks and uncertainties related to the impact of general economic, industry or political conditions in or internationally. Additional risks and uncertainties relating to the offering, and its business can be found under the caption “Risk Factors” included in AVEO’s Annual Report on Form 10-K for the year ended , AVEO’s prospectus supplement dated , which was filed with the on , and other filings that may make with the in the future.